Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Hau

Showing results (171-180 of 180) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 180 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 25, 2021
Severe Dysbiosis and Specific Haemophilus and Neisseria Signatures as Hallmarks of the Oropharyngeal Microbiome in Critically Ill Coronavirus Disease 2019 (COVID-19) PatientsJuliana de Castilhos, Eli Zamir, Theresa Hippchen, et al.
The Journal of Clinical Investigation|November 15, 2021
Metabolic imbalance of T cells in COVID-19 is hallmarked by basigin and mitigated by dexamethasonePeter J Siska, Sonja-Maria Decking, Nathalie Babl, et al.
The Lancet. Oncology|August 29, 2014
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trialRoger Stupp, Monika E Hegi, Thierry Gorlia, et al.
Lancet (London, England)|August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyMartin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
Lancet (London, England)|February 21, 2019
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Theophilos Tzaridis, Frederic Mack, et al.
The Lancet. Oncology|May 17, 2021
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, et al.
The Lancet. Oncology|December 25, 2025
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trialMartin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, et al.
Neuro-Oncology|October 23, 2024
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directionsMary Jane Lim-Fat, Julie Bennett, Quinn Ostrom, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2023
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419)Caroline Hertler, Jörg Felsberg, Dorothee Gramatzki, et al.
BMC Cancer|February 20, 2025
The ATLAS/NOA-29 study protocol: a phase III randomized controlled trial of anterior temporal lobectomy versus gross-total resection in newly-diagnosed temporal lobe glioblastomaMatthias Schneider, Anna-Laura Potthoff, Yahya Ahmadipour, et al.
Pageof 18

Showing results (171-180 of 180) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 180 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 25, 2021
Severe Dysbiosis and Specific Haemophilus and Neisseria Signatures as Hallmarks of the Oropharyngeal Microbiome in Critically Ill Coronavirus Disease 2019 (COVID-19) PatientsJuliana de Castilhos, Eli Zamir, Theresa Hippchen, et al.
The Journal of Clinical Investigation|November 15, 2021
Metabolic imbalance of T cells in COVID-19 is hallmarked by basigin and mitigated by dexamethasonePeter J Siska, Sonja-Maria Decking, Nathalie Babl, et al.
The Lancet. Oncology|August 29, 2014
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trialRoger Stupp, Monika E Hegi, Thierry Gorlia, et al.
Lancet (London, England)|August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyMartin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
Lancet (London, England)|February 21, 2019
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Theophilos Tzaridis, Frederic Mack, et al.
The Lancet. Oncology|May 17, 2021
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, et al.
The Lancet. Oncology|December 25, 2025
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trialMartin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, et al.
Neuro-Oncology|October 23, 2024
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directionsMary Jane Lim-Fat, Julie Bennett, Quinn Ostrom, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2023
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419)Caroline Hertler, Jörg Felsberg, Dorothee Gramatzki, et al.
BMC Cancer|February 20, 2025
The ATLAS/NOA-29 study protocol: a phase III randomized controlled trial of anterior temporal lobectomy versus gross-total resection in newly-diagnosed temporal lobe glioblastomaMatthias Schneider, Anna-Laura Potthoff, Yahya Ahmadipour, et al.
Pageof 18